We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Point-of-Care CD4 Counter Evaluated

By LabMedica International staff writers
Posted on 10 Jan 2013
The measurement of the absolute CD4 T-cell count is critical in the initial evaluation and staging of persons infected human immunodeficiency virus (HIV). More...


However, access to the technology that allows for such measurements remains limited in many low resource settings where disease burden of HIV and acquired immunodeficiency disease syndrome (AIDS) is highest.

Scientists at MBio Diagnostics (Boulder, CO, USA) working with colleagues at the University of California (San Diego, CA, USA) evaluated the performance of a prototype point-of-care device (POC) to quantify CD4 T cells. The device combines single-use, disposable cartridges with a simple reader instrument. Based on the principle of static imaging cytometry with fluorescent immunostaining, the system utilizes a novel, laser-based illumination approach combined with MBio's proprietary planar waveguide technology.

A total of 94 participants provided venous whole blood samples and 52 capillary whole blood specimens. Study participants were HIV-infected individuals enrolled through a large primary HIV care program, at the University of California, San Diego between May 2011 and October 2011. Participants were predominantly male, of Caucasian and Hispanic race/ethnicity, with a median age of 44 years. The device, known as the Snapcount system, is a product of MBio Diagnostics and was compared with conventional flow cytometry (FACSCalibur, Becton Dickinson).

The prototype MBio system showed negligible quantitative bias relative to flow cytometry. Higher variability was observed in the capillary samples relative to venipuncture, but system precision was good for both capillary and venipuncture samples. There was also close agreement between results from the same participant when tested with two different systems, different operators, and different locations.

The authors wrote that developmental efforts are underway on a cartridge that incorporate lyophilized reagents and allows direct whole blood addition combined with a reader device. The reader device would include an integrated touch screen, internal and external quality control features, and data management software and network connectivity. The study was published in the January 2013 edition of the Journal of Immunological Methods.


Related Links:
MBio Diagnostics
University of California San Diego
Becton Dickinson


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.